J
John F. Forbes
Researcher at University of Limerick
Publications - 373
Citations - 51254
John F. Forbes is an academic researcher from University of Limerick. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 88, co-authored 368 publications receiving 46433 citations. Previous affiliations of John F. Forbes include University of Newcastle & University of Melbourne.
Papers
More filters
Journal ArticleDOI
Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial
Ivana Sestak,Roseann Kealy,D. Michele Nikoloff,Marcel Fontecha,John F. Forbes,Anthony Howell,Jack Cuzick +6 more
TL;DR: Data from the preventive IBIS-I study did not support an association between the CYP2D6 phenotype and breast cancer outcome or the development of endocrine symptoms in tamoxifen-treated women.
Journal ArticleDOI
Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types
Sherene Loi,W. Fraser Symmans,John M. S. Bartlett,Debora Fumagalli,Laura van 't Veer,John F. Forbes,Philippe L. Bedard,Carsten Denkert,Jo Anne Zujewski,Giuseppe Viale,Lajos Pusztai,Laura J. Esserman,Brian Leyland-Jones +12 more
TL;DR: It is proposed that tumour tissue (formalin-fixed, paraffin-embedded and samples dedicated for molecular studies) should be taken at baseline, 1-3 weeks after the start of treatment, and at definitive surgery, with clear prioritisation in the study protocol of number, order, and preservation of samples to be gathered.
Journal ArticleDOI
Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor
Marco Colleoni,S. Li,R. D. Gelber,Alan S. Coates,M. Castiglione-Gertsch,Karen N. Price,J. Lindtner,C.-M. Rudenstam,Diana Crivellari,John P. Collins,Olivia Pagani,Edda Simoncini,Beat Thürlimann,Elizabeth Murray,John F. Forbes,D. Eržen,Stig Holmberg,Andrea Veronesi,A. Goldhirsch +18 more
TL;DR: CMF given concurrently (early, delayed or both) with tamoxifen was more effective than tamox ifen alone for patients with node-positive, endocrine-responsive breast cancer, supporting late administration of chemotherapy even after commencement of tamoxIFen.
Journal ArticleDOI
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial
Nicholas Zdenkowski,John F. Forbes,F.M. Boyle,George Kannourakis,Peter Grantley Gill,Evan Bayliss,Christobel Saunders,Stephen Della-Fiorentina,N. Kling,Ian G. Campbell,GB Mann,Alan S. Coates,Val Gebski,Lucy Claire Davies,R. M. Thornton,Linda Reaby,Jack Cuzick,Michael D. Green +17 more
TL;DR: These results should be considered exploratory, but lend weight to emerging data supporting longer duration endocrine therapy for hormone receptor-positive breast cancer, and offer insight into reintroduction of AI therapy.
Journal ArticleDOI
Long-term effects of adjuvant chemotherapy in breast cancer.
TL;DR: Late effects of adjuvant chemotherapy (ACT) may include second malignant neoplasms (SMN), cardiotoxicity and ovarian suppression, which are important for planning retreatments and combined modality protocols.